The acquisition will deliver strong commercial synergy with Hasten’s current critical care portfolio SHANGHAI, May 4, 2023 /PRNewswire/ — Hasten Biopharmaceutic Co., Ltd (China) (“Hasten”) today announced that it has acquired the commercial rights in China for Rocephin®, a long-acting,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.